Response rates and disease control rates within Fc gamma receptor (FCGR) polymorphisms
| FCGR2A HH vs non-HH | Best response | Total | |||
|---|---|---|---|---|---|
| CR | PR | SD | PD | ||
| FCGR 2A status (HH vs not HH) | |||||
| Non-HH | |||||
| Count | 5 | 130 | 168 | 123 | 426 |
| % within FCGR 2A status | 1.2 | 30.5 | 39.4 | 28.9 | 100.0 |
| HH | |||||
| Count | 3 | 55 | 93 | 62 | 213 |
| % within FCGR 2A status | 1.4 | 25.8 | 43.7 | 29.1 | 100.0 |
| Total | |||||
| Count | 8 | 185 | 261 | 185 | 639 |
| % within FCGR2A status | 1.3 | 29.0 | 40.8 | 29.0 | 100.0 |
| FCGR2A HH vs non-HH | Disease control | |
|---|---|---|
| PD | CR+PR+SD | |
| FCGR2A status (HH vs non-HH) | ||
| Non-HH | ||
| Count | 123 | 303 |
| % within FCGR2A status (HH vs non-HH) | 28.8 | 71.1 |
| % of total | 19.2 | 47.4 |
| HH | ||
| Count | 62 | 151 |
| % within FCGR2A status (HH vs non-HH) | 29.1 | 70.8 |
| % of total | 9.7 | 23.6 |
| Total | ||
| Count | 185 | 454 |
| % within FCGR3A status (HH vs non-HH | 29.0 | 71.0 |
| % of total | 29.0 | 71.0 |
| FCGR3A VV vs not VV | Best response | Total | |||
|---|---|---|---|---|---|
| CR | PR | SD | PD | ||
| FCGR 3A status (VV vs not VV) | |||||
| Non-VV | |||||
| Count | 6 | 157 | 231 | 153 | 547 |
| % within FCGR 3A status | 1.1 | 28.7 | 42.2 | 28 | 100 |
| VV | |||||
| Count | 2 | 30 | 35 | 38 | 105 |
| % within FCGR 3A status | 1.9 | 28.6 | 33.3 | 36.2 | 100 |
| Total | |||||
| Count | 8 | 187 | 266 | 191 | 652 |
| % within FCGR3A status | 1.2 | 28.7 | 40.8 | 29.3 | 100 |
| FCGR3A VV vs non-VV | Disease control | |
|---|---|---|
| PD | CR+PR+SD | |
| FCGR3A status (VV vs non-VV) | ||
| Non-VV | ||
| Count | 167 | 386 |
| % within FCGR3A status (VV vs non-VV) | 30.2 | 69.8 |
| % of total | 25.3 | 58.4 |
| VV | ||
| Count | 44 | 64 |
| % within FCGR3A status (VV vs non VV) | 40.7 | 59.3 |
| % of total | 6.7 | 9.7 |
| Total | ||
| Count | 211 | 450 |
| % within FCGR3A status (VV vs non-VV) | 31.9 | 68.1 |
| % of total | 31.9 | 68.1 |
PD, progressive disease; PR, partial response.